Autolus Therapeutics (AUTL) vs Capricor Therapeutics (CAPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 21.5% versus a gain of 8.0%. Over five years, CAPR leads with a +104.5% price change compared with -70.5% for AUTL. Capricor Therapeutics is the larger company by market cap ($465.7 million vs $463.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | CAPR |
|---|---|---|
| Share price | $1.74 | $8.01 |
| Market cap | $463.12M | $465.69M |
| 1-day change | -3.87% | -1.11% |
| YTD return | -9.05% | -71.93% |
| 1-year return | +21.48% | +8.00% |
| 5-year return | -70.52% | +104.55% |
| EPS (TTM) | $-1.06 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $40.37 |
| 52-week low | $1.18 | $2.96 |
| Distance from 52-week high | -32.56% | -80.16% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +401.72% | +237.08% |
| Average volume | 2.10M | 6.85M |
| Shares outstanding | 266.16M | 58.14M |
| Employees | 752 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed CAPR by 13.5 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
AUTL vs CAPR FAQ
Which is bigger, Autolus Therapeutics or Capricor Therapeutics?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $465.69M compared with $463.12M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, AUTL or CAPR?
AUTL returned +21.48% over the past 12 months, compared with +8.00% for CAPR (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Capricor Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Autolus Therapeutics and Biotechnology: Pharmaceutical Preparations for Capricor Therapeutics.